Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Next Previous
Trial Profile

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALLO 647 (Primary) ; Cemacabtagene ansegedleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ExPAND
  • Sponsors Allogene Therapeutics

Most Recent Events

  • 30 May 2024 Status changed from recruiting to active, no longer recruiting.
  • 04 Jan 2024 According to an Allogene Therapeutics media release, differentiated potential for cema-cel to boost cure rates in the 1l setting expected to decrease demand for later line treatment, effectuating de-prioritization of third line alpha2 and expand trials
  • 03 May 2023 According to an Allogene Therapeutics media release, the company initiated phase 2 EXPAND trial to support licensure of ALLO-647 as a lymphodepleting agent for ALLO-501A

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top